DBV Technologies is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel treatments for patients with food allergies and other immunological diseases. Their proprietary Viaskin™ platform is an investigational epicutaneous immunotherapy (EPIT™) method designed to deliver biologically active compounds to the immune system through intact skin. DBV's primary focus is on food allergies, with its lead product candidate, Viaskin™ Peanut, being developed for the treatment of peanut allergy in children aged 1 to 3 years. The company aims to provide safe, effective, and patient-friendly solutions to address significant unmet medical needs in allergy care.
Serves as the central hub for research and development, corporate strategy, administrative functions, and European operations.
Modern office and laboratory facilities designed to support biopharmaceutical research and development activities.
A science-driven, innovative, and collaborative environment focused on advancing allergy treatments. Emphasis on patient impact and scientific rigor.
The Montrouge headquarters is critical for DBV's core R&D efforts, global operational oversight, and strategic decision-making for its Viaskin platform.
DBV Technologies operates with a focused global strategy, primarily centered in Europe and North America. Its headquarters in France drives global research, development, and corporate functions. The U.S. office is crucial for clinical trials, FDA interactions, and future commercialization in the significant North American market. While manufacturing partnerships may extend their reach, their direct operational presence is concentrated in these key pharmaceutical regions to advance their allergy immunotherapy pipeline worldwide.
177-181 avenue Pierre Brossolette
Montrouge
Île-de-France
France
Address: 150 Allen Road, Basking Ridge, NJ 07920, USA
To facilitate engagement with the U.S. Food and Drug Administration (FDA), manage clinical trial sites across North America, and build a commercial presence for future product launches in the U.S. market.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, DBV Technologies' leadership includes:
DBV Technologies has been backed by several prominent investors over the years, including:
Over the last 12-18 months, DBV Technologies has significantly strengthened its executive team with several key appointments, indicating a period of strategic reinforcement. No major executive departures have been publicly announced in the immediate past 12 months (May 2023-May 2024), suggesting leadership stability focused on advancing clinical programs.
Discover the tools DBV Technologies uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
DBV Technologies commonly uses the email format combining the first initial and last name. Understanding this pattern can be helpful for professional communication.
[first_initial][last]@dbv-technologies.com
Format
jdoe@dbv-technologies.com
Example
85%
Success rate
GlobeNewswire • May 2, 2024
DBV Technologies announced its financial results for the first quarter of 2024, highlighting a cash position of $108.5 million. The company continues to focus on the VITESSE Phase 3 clinical trial for Viaskin Peanut in children aged 1-3 and is preparing for potential BLA submission....more
GlobeNewswire • March 7, 2024
DBV Technologies provided its full-year 2023 financial results and a business update, detailing progress on its clinical programs, particularly the Viaskin Peanut EPIT development. The company reiterated its commitment to advancing treatments for food allergies....more
European Pharmaceutical Review • February 26, 2024
A study (PEOPLE Phase III) showed long-term clinical benefits of Viaskin Peanut epicutaneous immunotherapy (EPIT) for children with peanut allergies aged four to 11 years. Findings suggest sustained desensitisation even after treatment cessation....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including DBV Technologies, are just a search away.